肿瘤细胞的特异性识别和结合是实现肿瘤靶向治疗的关键，缺乏有效靶标仍然是肿瘤靶向治疗面临的主要问题。糖代谢标记以其可以进行活体标记并且具有密度高、毒性低、干扰小等特点，使其能够为肿瘤靶向治疗提供新的策略。基于糖代谢标记策略，可以对肿瘤细胞进行半抗原、抗原、化疗药物及细胞毒性药物等的标记，从而实现对肿瘤细胞的特异性识别，或激活机体的细胞和体液免疫应答，还可以通过标记免疫细胞增加其对肿瘤细胞的特异性识别和结合。糖代谢标记在肿瘤靶向治疗中具有广阔的应用前景。

The specific recognition and binding of tumor cells are crucial to targeted therapy. However, lacking effective targets is still the main challenge for targeted therapy. Glycan metabolic labeling provides a potential approach for tumor targeted therapy with advantages of in vivo labeling, high labeling efficiency, low toxicity and less interference. Through labeling tumor cells with hapten, antigen, chemotherapeutic drugs and cytotoxic drugs, labeling strategy based on glycan metabolism realizes the specific recognition of tumor cells or stimulates cellular and humoral immune responses in vivo. In addition, through labeling immune cells, this strategy also improves immune cells’specific recognition and binding of tumor cells. The strategy of glycan metabolic labeling provides broad application prospects in tumor targeted therapy.

R730.54；Q591.4

国家自然科学基金资助项（No.31770987；No.81971497；No.21907022）；河南省自然科学基金优秀青年项目资助（No. 202300410037）